A Randomized, Phase I/II Clinical Trial Evaluating the Safety, Reactogenicity, and Immunogenicity of Licensed Trivalent Influenza Vaccine Administered With Recombinant Interferon Alpha Among Patients With Chronic Lymphocytic Leukemia

NCT00962715 Phase 1/Phase 2 WITHDRAWN

The goal of this clinical study is to learn if Pegasys (pegylated interferon) or Roferon (interferon) can make the Trivalent Inactivated Influenza vaccine (TIV) more effective in increasing the body's immune reaction against the flu virus in patients with Chronic Lymphocytic Leukemia (CLL).

Details

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1/Phase 2
Status	WITHDRAWN
Start date	2011-04

Conditions

• Chronic Lymphocytic Leukemia

Interventions

• Influenza Vaccine Trivalent Inactivated (TIV)
• Pegylated interferon (PEGrIFN-α, Pegasys)
• Interferon (IFNα, Roferon-A)

Primary outcomes

• Immunogenicity rate — Day 1, 8, 28, 56 and 6 Months